<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022420</url>
  </required_header>
  <id_info>
    <org_study_id>SATORI (29BRC21.0089)</org_study_id>
    <nct_id>NCT05022420</nct_id>
  </id_info>
  <brief_title>SAfety and TOlerance of the Biopsies in Auto-immune Rare dIseases</brief_title>
  <acronym>SATORI</acronym>
  <official_title>SAfety and TOlerance of the Biopsies in Auto-immune Rare dIseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biopsies are performed in several autoimmune diseases to diagnose or classify them Tolerance&#xD;
      and information of the patients have been poorly evlauated our objective is to evaluate&#xD;
      tolerance and information of the patients after the biopsies for salivary gland, temporal&#xD;
      arteries and neuromuscular.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patinets that benefited of arterial temporal biospy or salivary gland biospy or muscuar&#xD;
      biopsy or neuro muscular biospy for his auto -mmune disease will be included and fill&#xD;
      standardized questionnaires concerning tolerance, information and side effect at inclusion ,&#xD;
      day 7 and day 30 after the biopsy data will be analysed to evaluate information, tolerance&#xD;
      and risk factor af side effect&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">September 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 19, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>tolerance of each type of biopsy</measure>
    <time_frame>tolerance at day 7 after the biospy was performed</time_frame>
    <description>tolerance based on a standardized patient 's questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tolerance of each type of biopsy 30 days after</measure>
    <time_frame>tolerance at day 30 and at inclusion after the biospy was performed</time_frame>
    <description>tolerance based on a standardized patient 's questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of the qualitiy of patient's information at inclusion</measure>
    <time_frame>questionnaire at inclusion</time_frame>
    <description>standardized questionnaire at inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk factor of sied effect of each biospy</measure>
    <time_frame>standardized questionnaire at inclusion, day 7 and 30</time_frame>
    <description>standardized questionnaire</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Tolerance</condition>
  <condition>Biopsy Site Itching</condition>
  <arm_group>
    <arm_group_label>Salivary gland biospy,</arm_group_label>
    <description>100 Salivary gland biospy use for the diagnosis of sjogern disease or other auto-immune disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>muscular biopsy,</arm_group_label>
    <description>muscular biospy use for the diagnosis of muscular auto-immune disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neuro muscular biospy</arm_group_label>
    <description>neuro muscular biospy use for the diagnosis of vasculitis,muscular auto-immune disease or neuro-muscumar auto-immune disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>temporal arteries biospy</arm_group_label>
    <description>temporal arteries biospy uses for the diagnosis of giant cell arteritis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        all patients that underwent a biospy for his auto-immune rare disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  biospy required for the diagnsis or follow up aged of more than 18 non opposition form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unable to consent demencia unable to fill the form and questionnaire patient Under&#xD;
             juridical protection refusing to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valérie Devauchelle-Pensec</last_name>
    <phone>02-98-34-72-64</phone>
    <email>valerie.devauchelle-pensec@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alain Saraux</last_name>
    <phone>02 98 34 72 64</phone>
    <email>alain.saraux@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'ANGERS</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geoffrey URBANSKI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe RICHEZ RICHEZ</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Devauchelle-Pensec</last_name>
      <email>valerie.devauchelle-pensec@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de LILLE</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric HACHULLA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle CAMPANA-SALORT -</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves ALLENBACH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillermo CARVAJAL ALEGRIA</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rare Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning one year and ending five years following the publication</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

